

Executive Management

Timothy P. Walbert

Chairman, President and Chief Executive Officer

Brian K. Beeler

Executive Vice President, General Counsel

Robert F. Carey

Executive Vice President, Chief Business Officer

Michael DesJardin

Executive Vice President, Technical Operations

George Hampton

Executive Vice President, Primary Care Business Unit

Dave Happel

Executive Vice President, Orphan Business Unit

Paul W. Hoelscher

Executive Vice President, Chief Financial Officer

Vikram Karnani

Senior Vice President, Rheumatology Business Unit

Barry J. Moze

Executive Vice President, Chief Administrative Officer

Jeffrey W. Sherman, M.D., FACP

Executive Vice President, Research and Development and Chief Medical Officer

Corporate Media Contact:

Geoffrey M. Curtis
media@horizonpharma.com

Ireland Media Contact:

Ray Gordon
ray@gordonmrm.ie

Investor Relations Contact:

Tina Ventura
investor-relations@horizonpharma.com

Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets eleven medicines through its orphan, rheumatology and primary care business units.

Key Products

For safety information, see product websites



For reducing the frequency and severity of serious infections associated with chronic granulomatous disease (CGD) and for delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO). www.ACTIMMUNE.com⁽¹⁾



As adjunctive therapy in the chronic management of patients with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). www.horizonpharma.com⁽¹⁾



For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers in patients at risk of developing NSAID-associated gastric ulcers. www.DUEXIS.com⁽¹⁾



KRYSTEXXA® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. www.KRYSTEXXA.com⁽¹⁾



MIGEROT® is the only FDA approved ergotamine suppository for the treatment of migraines. www.MIGEROT.com⁽¹⁾



For treatment of pain of osteoarthritis of the knee(s). www.PENNSAID.com⁽¹⁾



PROCYSBI is the first cystine-depleting agent given every 12 hours that is approved in the United States for the treatment of nephropathic cystinosis in adults and children 2 years of age and older. www.PROCYSBI.com⁽¹⁾



Management of chronic pulmonary infections due to *Pseudomonas aeruginosa* in adult patients with cystic fibrosis. Not available in the United States.



For use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. www.RAVICTI.com⁽¹⁾



For treatment of rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma, and chronic obstructive pulmonary disease and other indications. www.RAYOSrx.com⁽¹⁾



For the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. www.VIMOVO.com⁽¹⁾

Corporate Locations

Corporate Headquarters

U.S. Operations

Horizon Pharma AG

Horizon Pharma GmbH

Connaught House, 1st Floor
1 Burlington Road
Dublin 4, Ireland DO4 C5Y6
+353 1 772 2100

150 S Saunders Road
Lake Forest, IL 60045
+1 224.383.3000

150 S Wacker Drive
Suite 3200
Chicago, IL 60606

Kägenstrasse 17
CH-4153 Reinach,
Switzerland
+41 61 715 20 40

Joseph-Meyer-Str. 13-15
D-68167 Mannheim,
Germany
+49 621 43 85 020

Board of Directors

Timothy P. Walbert

Chairman, President and Chief Executive Officer

Michael Grey

Executive Chairman, Amplyx Pharmaceuticals, Inc. and Chairman and Chief Executive Officer, Reneo Pharmaceuticals, Inc.

Liam Daniel

Director, Malin Corporation plc

Jeff Himawan, Ph.D.

Managing Director, Essex Woodlands Health Ventures, L.P.

Ronald Pauli

Chief Financial Officer, BioQ Pharma, Inc.

Gino Santini

Chairman, AMAG Pharmaceuticals, Inc.

H. Thomas Watkins

Chairman, Vanda Pharmaceuticals Inc.

Recent Acquisitions

River Vision Development Corp.

In May 2017, completed the acquisition of River Vision and teprotumumab (RV001), a fully human antibody expected to enter Phase 3 clinical development in 2H17.

Raptor Pharmaceutical Corp.

In October 2016, completed the acquisition of Raptor Pharmaceutical Corp., which added PROCYSBI® and QUINSAIR™.

Crealta Holdings LLC

In January 2016, completed the acquisition of Crealta Holdings LLC, which added KRYSTEXXA® (pegloticase), a biologic medicine for refractory chronic gout.

Key Figures⁽²⁾


Closing Share Price	\$10.83
Ordinary Shares Outstanding	164.9 million
Market Capitalization	\$1.8 billion
Global Employees	>1,050

Analyst Coverage

BMO Citi Cowen
JMP Securities Jefferies
Mizuho Morgan Stanley
Piper Jaffray Stifel UBS

Financial Performance

Annual Performance



(1) See product website for Full Prescribing Information, Important Safety Information and on Boxed Warning.

(2) Closing share price and market capitalization as of May 16, 2017. Weighted average shares outstanding - diluted for the three months ended March 31, 2017.

(3) Please refer to the GAAP to non-GAAP reconciliations included under "Financial Information" in the Investors section of www.horizonpharma.com for a reconciliation of the non-GAAP items for 2011, 2012, 2013, 2014, 2015 and 2016.

(4) On Sept. 26, 2016, Horizon Pharma agreed to pay Express Scripts \$65 million as part of a litigation settlement, which was recorded as a one-time reduction to GAAP net sales for the twelve months ended December 31, 2016, in accordance with U.S. GAAP. The exclusion of the \$65 million settlement from GAAP net sales is the only adjustment reflected in year-to-date non-GAAP adjusted net sales.

(5) Estimate based on financial guidance issued May 8, 2017.